Thromboangiitis obliterans (Buerger's disease)
- Authors: Sapelkin S.V1, Druzhinina N.A1
-
Affiliations:
- A.V.Vishnevsky National Medical Research Center of Surgery of the Ministry of Health of the Russian Federation
- Issue: Vol 20, No 8 (2018)
- Pages: 91-95
- Section: Articles
- URL: https://journals.rcsi.science/2075-1753/article/view/95123
- DOI: https://doi.org/10.26442/2075-1753.2018.8.91-95
- ID: 95123
Cite item
Full Text
Abstract
Thromboangiitis obliterans is a chronic inflammatory disorder that mostly manifests in young patients. The primary vessel wall lesion leads to further necrosis without affecting elastic vessel membrane. Generally thromboangiitis involves peripheral arteries resulting in typical clinical presentation of limb ischemia. Veins are involved as well as arteries whereas no signs of atherosclerosis are found in these patients. Thromboangiitis may be acute as well as it may have relapsing-remitting course causing thromboses and limb ischemia that may result in limb loss. Patients’ survival is higher than corresponding survival rates in patients with atherosclerosis even despite unfavorable outcome of limb revascularization. It is explained by absence of coronary atherosclerosis in these patients. Taking into account the ongoing research on pathogenesis, treatment of such patients still remains a subject of discussion and is a promising area for further scientific developments.
Full Text
##article.viewOnOriginalSite##About the authors
S. V Sapelkin
A.V.Vishnevsky National Medical Research Center of Surgery of the Ministry of Health of the Russian Federation
Email: sapelkin@ixv.ru
д-р мед. наук, вед. науч. сотр. отд-ния сосудистой хирургии 117997, Russian Federation, Moscow, ul. Bol'shaia Serpukhovskaia, d. 27
N. A Druzhinina
A.V.Vishnevsky National Medical Research Center of Surgery of the Ministry of Health of the Russian Federation
Email: dna13@mail.ru
клин. ординатор отд-ния сосудистой хирургии 117997, Russian Federation, Moscow, ul. Bol'shaia Serpukhovskaia, d. 27
References
- Olin J.W. Thromboangiitis obliterans (Buerger’s disease). N Engl J Med 2000; 82 (343): 864-9.
- Buerger L. Thrombo-angiitis obliterans: a study of the vascular lesion leading to presenile spontaneous gangrene. Am J Med Sci 1908; 136: 567-80.
- Szuba A, Cooke J.P. Thromboangiitis obliterans. An update of Buerger’s disease. West J Med 1998; 168: 255-60.
- Aerbajinai W, Tsuchiya T, Kimura A et al. HLA class II DNA typing in Buerger's disease. Int J Cardiol 1996; 54 (Suppl): S197-202.
- Sayin A.I, Bozkurt A.K, Tüzün H et al. Surgical treatment of Buerger's disease: experience with 216 patients. Cardiovasc Surg 1993; 1 (4): 377-80.
- Клиническая ангиология: руководство. Под ред. А.В.Покровского. В 2 т. Т. 2. М.: Медицина, 2004.
- Sasaki S, Sakuma M, Yasuda K. Current status of thromboangiitis obliterans (Buerger’s disease) in Japan. Int J Cardiol 2000; 75: S175-S181.
- Wysokinski W.E, Kwiatkowska W, Sapian-Raczkowska B et al. Sustained classic clinical spectrum of thromboangiitis obliterans (Buerger’s disease). Angiology 2000; 51: 141-50.
- Oral iloprost in the treatment of thromboangiitis obliterans (Buerger’s disease): double-blind, randomized, placebo-controlled trial. The European TAO Study Group. Eur J Vasc Endovasc Surg 1998; 15: 300-7.
- Национальные рекомендации по ведению пациентов с заболеваниями артерий нижних конечностей. Российский согласительный документ. М., 2013
- Norgren L, Hiatt W.R, Dormandy J.A. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). J Vasc Surg 2007; 45 (Suppl. S): S5-67.
- Gerhard-Herman M.D et al. 2016 AHA/ACC Guideline on the Management of Patients With Lower Extremity Peripheral Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am College Cardiol 2016.
- Aboyans V et al. 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS). Eur Heart J 2017; 00: 1-60.
- Anand S.S et al. Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet 2017. doi: 10.1016/S0140-6736(17)32409-1
